Re-thinking neuropeptide therapeutics: What Neuropeptide Y and Galanin teach us about stress, resilience, and drug...

Neuropeptide Y (NPY) and galanin (GAL), two of the most abundant neuropeptides in the mammalian nervous system, are consistently associated with brain disorders, yet their therapeutic potential remains unrealized. Both are state-dependent modulators that are released under physiological load, acting as adaptive circuit stabilizers. Both have generated expensive drug programs that failed, not because the biology was wrong, but because the development strategy was. This manuscript uses NPY and GAL as paired case studies to argue that inconsistent translation reflects strategy mismatch in target selection, modality, dosing logic, and endpoint design, rather than weak targets. We synthesize molecular organization, structural biology, circuit function and human genetic evidence, and dissect clinical failures. We close with a concrete, indication-anchored development roadmap to maximize NPY and GAL drug development potential.